Securities code: 603392 securities abbreviation: Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) Announcement No.: 2022-019 Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392)
Reduction of shares held by senior managers through centralized bidding
Half time and progress announcement
The board of directors, all directors and relevant shareholders of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. Important content tips:
Basic information of shareholding of senior managers
As of the disclosure date of the reduction plan (November 23, 2021), Mr. Li Yimin, chief engineer of Beijing Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) Pharmaceutical Co., Ltd. (hereinafter referred to as “the company”), held 4506915 shares of the company, accounting for 0.7424% of the total share capital of the company, The above shares come from the existing shares before the company’s initial public offering and listing and the shares obtained after the company implements the 2020 dividend distribution plan, that is, 4 shares for every 10 shares. Progress of centralized bidding reduction plan
On February 7, 2022, the company received the notification letter on the progress of share reduction sent by Mr. Li Yimin, which is more than half of the planned time. As of the disclosure date of this announcement, Mr. Li Yimin has reduced 0 shares of the company through centralized bidding trading and 470000 shares of the company through block trading. In total, he has reduced 470000 shares of the company, accounting for 0.0774% of the total share capital of the company. The reduction plan has not been implemented yet. 1、 Basic information of the subject of centralized bidding reduction before reduction
Shareholder name shareholder identity shareholding number (shares) shareholding proportion current shareholding source
Directors, supervisors and pre IPO acquisition: 3009128 shares, Li Yimin 4506915 0.7424%
Acquired by senior managers in other ways: 1497787 shares
The above reduction subjects have no concerted action.
2、 Disclosure of the progress of the implementation of the bidding reduction plan (I) due to the following reasons:
The reduction time is more than half
Reduction price reduction total current shareholding
Current range of shareholders’ holdings (yuan amount)
Name proportion period mode share proportion (share) / share (yuan) (share)
2021 / 12 / 15 ~ centralized competition
Li Yimin 0% 0 – 0 0 4036915 0.6650% 2022 / 2 / 7 price transaction
Note: in addition to the reduction of shares by the above centralized bidding method, Mr. Li Yimin on December 8, 2021 and December 9, 2021
250000 shares and 220000 shares of the company were reduced through block trading, accounting for 0.0774% of the total share capital of the company. (II) whether the reduction is consistent with the plans and commitments previously disclosed by the directors, supervisors and senior management √ yes □ no (III) whether the listed company discloses major matters such as high-tech transfer or planning merger and reorganization within the reduction time interval □ yes √ no (IV) the impact of the reduction on the company
This share reduction plan is independently decided by Mr. Li Yimin according to his personal capital needs. It is a normal share reduction behavior of shareholders and will not have a significant impact on the corporate governance structure, equity structure and future sustainable operation, and will not lead to changes in the company’s control. (V) other matters required by the exchange
The company will continue to pay attention to the implementation of Mr. Li Yimin’s share reduction plan, urge him to strictly abide by relevant laws and regulations, departmental rules and relevant requirements of normative documents, and timely fulfill the obligation of information disclosure. 3、 Risk tips related to the reduction plan of centralized bidding (I) uncertainty risk of the implementation of the reduction plan
Mr. Li Yimin’s share reduction plan has not been implemented yet. During the reduction period, the shareholder will decide to implement the share reduction plan according to the market conditions, the company’s share price and other factors. There are uncertainties in the reduction time, reduction quantity and reduction price.
(II) whether the implementation of the share reduction plan will lead to the risk of change in the control of the listed company □ yes √ no (III) other risks
The reduction plan complies with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, several provisions on the reduction of shares by shareholders, directors, supervisors and senior managers of listed companies, the implementation rules for the reduction of shares by shareholders, directors, supervisors and senior managers of listed companies on Shanghai Stock Exchange and other laws, regulations, departmental rules and normative documents, There is no circumstance in which the shares shall not be reduced.
During the reduction period, the company will timely perform the obligation of information disclosure in accordance with relevant regulations.
It is hereby announced.
Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) board of directors February 8, 2022
